Meeting
2016 ASCO Annual Meeting
Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer.
Authors
Hongjae Chon
Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea., Seongnam, Korea, The Republic of
Hongjae Chon , Chan Kim , Minkyu Jung , Seungtaek Lim , Joo Hoon Kim , Ji Soo Park , Hyo Song Kim , Seung Hoon Beom , Hyun Cheol Chung , Sun Young Rha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01283204
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4063)
DOI
10.1200/JCO.2016.34.15_suppl.4063
Abstract #
4063
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Class III β-tubulin as a predictive marker for taxane-based first-line palliative chemotherapy in recurrent or metastatic gastric cancer.
First Author: Jun-Eul Hwang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz